David K. Heidary

Vertex Pharmaceuticals (United States)

Papers

1

Total Citations

160

H-Index

1

About

David K. Heidary is a pioneering biochemist whose work has fundamentally advanced the field of high-throughput drug discovery. His primary research focuses on the development of innovative assay technologies for protein kinases and phosphatases—enzymes central to cell signaling, proliferation, and metabolism. Heidary’s most influential contribution is the creation of a FRET-based assay platform for ultra-high density drug screening, detailed in his 2002 paper, which has garnered over 160 citations. This breakthrough enabled the rapid, sensitive detection of kinase and phosphatase activity, dramatically accelerating the identification of potential therapeutic compounds. By addressing the critical need for efficient screening methods in drug development, Heidary’s work has had a lasting impact on pharmaceutical research, particularly in targeting aberrant enzyme activity linked to diseases like cancer. His achievements underscore a career dedicated to bridging fundamental enzymology with practical, high-impact applications, making him a key figure in the evolution of modern drug screening technologies.

Research Focus

Key Achievements

1
H-Index
1
Papers
160
Total Citations
160
Avg Citations/Paper
🏆 Most Cited Paper
A FRET-Based Assay Platform for Ultra-High Density Drug Screening of Protein Kinases and Phosphatases
160 citations · 2002
📈 Most Prolific Year: 2002 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Vertex Pharmaceuticals (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago